(Teleborsa) – Marked increase for Garofalo Health Care, which has a profit of 1.01% on previous values after announcing a positive half-year report.
As of June 30, 2021 i consolidated revenues GHC amounted to 133.5 million, an increase of 48.5% compared to 89.9 million recorded in the first half of 2020, the latter “influenced, starting from March, by the national and local regulatory restrictions imposed for tackle the Covid-19 pandemic ”. L’Operating EBITDA Adjusted consolidated amounted to 24.7 million, an increase of 120.4% compared to 11.2 million in the previous year, “a period influenced by the suspension of activities imposed starting from the month of March which had not allowed the full absorption of fixed costs”.
L’EBIT Adjusted it amounted to 16.5 million, an increase of 11.5 million compared to 5 million in the half year of a year ago. The Net income attributable to the Group amounted to 9.8 million (up almost eight times compared to 1.2 million in 1H2020) and is affected by the 2.5 million non-core costs relating to “Covid extra-costs” and costs M&A mentioned above. As of June 30, 2021 the Net Financial Position (NFP) of GHC amounted to 108.1 million, up by 10.4 million against 97.7 million in 2020, and is made up of financial debt for 153.4 million and liquidity for 45.3 million .
On a comparative basis on a weekly basis, the trend of Garofalo Health Care shows a more marked trend than the trendline of FTSE Italia Star. This demonstrates the greater propensity to buy by investors towards Garofalo Health Care with respect to the index.
Technically, Garofalo Health Care it is in a strengthening phase with an area of resistance seen at Euro 6.04, while the most immediate support is seen at 5.92. At the operational level, the session is expected to continue under the banner of bull with resistance seen at 6.16.
.
